BioCentury
ARTICLE | Company News

Advaxis, Aratana deal

March 24, 2014 7:00 AM UTC

Advaxis granted animal health company Aratana exclusive, worldwide rights to develop and commercialize ADXS-cHER2 to treat osteosarcoma in dogs as well as three undisclosed cancer immunotherapy products to treat three other types of animal cancers. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing to treat human cancers. ...